Trevi Therapeutics, Inc. (TRVI)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 14/100 (LOW), 78.4 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 10.24% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Trevi Therapeutics (TRVI) Stock Trades At A Premium To Fair Value
- Trevi Therapeutics to Participate in Upcoming September Conferences
- Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026
- Trevi Therapeutics Announces Upcoming June and July Event Schedule
- Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters.
- Trevi Therapeutics Q1 Earnings Call Highlights
- Trevi Therapeutics Maps Haduvio Chronic Cough Push, Sees Cash Runway Into 2030
- Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Trevi Therapeutics, Inc..
Full TRVI Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.